Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults

被引:0
|
作者
Shin, Thomas [1 ]
Wells, Chad R. [2 ]
Shoukat, Affan [3 ]
Potter-Schwartz, Lilia [2 ]
Langevin, Edith [4 ]
Langley, Joanne M. [5 ]
Galvani, Alison P. [2 ]
Moghadas, Seyed M. [6 ]
机构
[1] Sanofi, Hlth Econ & Outcomes Res, Bridgewater, NJ USA
[2] Yale Sch Publ Hlth, Ctr Infect Dis Modeling & Anal, New Haven, CT USA
[3] Univ Regina, Dept Math & Stat, Regina, SK, Canada
[4] Sanofi, Hlth Econ Value Assessment, Lyon, France
[5] Dalhousie Univ, Canadian Ctr Vaccinol, Halifax, NS, Canada
[6] York Univ, Agent Based Modelling Lab, 4700 Keele St, Toronto, ON M3J 1P3, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
AGED; 13-17; YEARS; UNITED-STATES; EPIDEMIOLOGY; PREVENTION; COVERAGE;
D O I
10.1001/jamanetworkopen.2024.43551
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance Beginning in 2005, the US implemented routine immunization of adolescents with a quadrivalent conjugate vaccine (MenACWY) for the prevention of invasive meningococcal disease (IMD). Objectives To assess whether MenACWY immunization was associated with a reduced IMD burden among the US adolescent population and how the downward trajectory of IMD that began in the mid-1990s might have evolved in the absence of vaccination efforts. Design, Setting, and Participants In this decision analytical study, a bayesian hierarchical Poisson regression model was developed to investigate the potential trajectory of IMD among US adolescents and young adults without vaccination and evaluate the direct association of vaccination with IMD burden. The model included the entire age-stratified US population and was fitted to national incidence data for serogroups C, W, and Y from January 1, 2001, to December 31, 2021, with stratification by vaccination status for IMD cases. Intervention Simulated counterfactual scenario of absent vaccination from 2005 to 2021, while retaining the incidence rate of IMD for unvaccinated individuals estimated during model fitting. Main Outcomes and Measures The main outcomes were the estimated numbers of IMD cases and deaths averted by MenACWY vaccination among US adolescents and young adults aged 11 to 23 years. Results Among the entire US population from 2005 to 2021, MenACWY vaccination prevented an estimated 172 (95% credible interval [CrI], 85-345) cases of IMD among US adolescents 11 to 15 years of age and 328 (95% CrI, 164-646) cases of IMD among those aged 16 to 23 years. Absent vaccination, the cumulative incidence of IMD in these age groups would have been at least 59% higher than reported over the same period with vaccination. Using case fatality rates of unvaccinated individuals derived from national data, vaccination averted an estimated 16 (95% CrI, 8-31) deaths among adolescents aged 11 to 15 years and 38 (95% CrI, 19-75) deaths among those aged 16 to 23 years. Conclusions and Relevance This decision analytical model suggests that the MenACWY vaccination program in the US was associated with a reduced burden of meningococcal disease. Without vaccination, the incidence rates per 100 000 adolescents and young adults would have been substantially higher than those observed during the vaccine era.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Invasive meningococcal disease in adolescents and young adults
    Harrison, LH
    Pass, MA
    Mendelsohn, AB
    Egri, M
    Rosenstein, NE
    Bustamante, A
    Razeq, J
    Roche, JC
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (06): : 694 - 699
  • [2] Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents
    Jackson, Lisa A.
    Baxter, Roger
    Reisinger, Keith
    Karsten, Annette
    Shah, Jina
    Bedell, Lisa
    Dull, Peter M.
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (01) : E1 - E10
  • [3] Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in Adolescents
    Jacobson, Robert M.
    Jackson, Lisa A.
    Reisinger, Keith
    Izu, Allen
    Odrljin, Tatjana
    Dull, Peter M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (04) : E170 - E177
  • [4] Antibody Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents
    Baxter, Roger
    Reisinger, Keith
    Block, Stanley L.
    Izu, Allen
    Odrljin, Tatjana
    Dull, Peter
    JOURNAL OF PEDIATRICS, 2014, 164 (06): : 1409 - +
  • [5] Meningococcal Quadrivalent (Serogroups A, C,W135, and Y) Conjugate Vaccine (Menveo®)In Adolescents and Adults
    Emma D. Deeks
    BioDrugs, 2010, 24 : 287 - 297
  • [6] Meningococcal Quadrivalent (Serogroups A, C, W135, and Y) Conjugate Vaccine (Menveo®) In Adolescents and Adults
    Deeks, Emma D.
    BIODRUGS, 2010, 24 (05) : 287 - 297
  • [7] KNOWLEDGE OF INVASIVE MENINGOCOCCAL DISEASE AND VACCINATION RECOMMENDATIONS FOR ADOLESCENTS AND YOUNG ADULTS AMONG US PHYSICIANS
    Herrera-Restrepo, Oscar
    Bunniran, Su
    Mond, Tiffany
    Davenport, Eric
    Wang, Jinyi
    Marshall, Gary S.
    JOURNAL OF ADOLESCENT HEALTH, 2023, 72 (03) : S89 - S90
  • [8] Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults
    Lee, Hoan Jong
    Chung, Moon-Hyun
    Kim, Woo Joo
    Hong, Young Jin
    Choi, Kyong Min
    Lee, Jina
    Oh, Chi Eun
    Welsch, Jo Anne
    Kim, Kyung-Hyo
    Hong, Ki Bae
    Dagnew, Alemnew F.
    Bock, Hans
    Dull, Peter M.
    Odrljin, Tatjana
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 28 : 204 - 210
  • [9] Meningococcal serogroup C serum and salivary antibody responses to meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with bivalent and quadrivalent meningococcal polysaccharide vaccine
    Khalil, Mohamed
    Al-Mazrou, Yagob
    Findlow, Helen
    Chadha, Helen
    Castells, Valerie Bosch
    Oster, Philipp
    Borrow, Ray
    VACCINE, 2014, 32 (43) : 5715 - 5721
  • [10] Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age
    Baxter, Roger
    Baine, Yaela
    Ensor, Kathleen
    Bianco, Veronique
    Friedland, Leonard R.
    Miller, Jacqueline M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (03) : E41 - E48